Asieris Pharma appoints Dr Linda Wu as Chief Development Officer

Asieris Pharmaceuticals, a China-based biopharma company specialising in discovering, developing and commercialising innovative drugs for the treatment of genitourinary tumours and other related diseases, has announced that Linda Wu, PhD will join Asieris as Chief Development Officer.

Chaitanya Sarawate steps in as India MD for Wipro GE Health Care

Wipro GE HealthCare has announced the appointment of Chaitanya Sarawate as the Managing Director (MD), Wipro GE HealthCare and President & CEO, GE HealthCare South Asia.

Goa Institute of Management launches professional certificate programme in healthcare

Goa Institute of Management (GIM) in India has launched a Professional Certificate Programme in Healthcare Management powered by Asia’s largest higher Edtech Company, upGrad.

Singapore unveils talent development strategy to boost Healthtech and Biotech ecosystem

Considering Singapore’s RIE2025 initiative, SGInnovate’s Helix Immersion Programme will support Singapore’s growing biomedical and biotech companies.

VALUE is the Trending Word of 2023

The last two years saw a significant leap toward patient-centricity in the pharmaceutical space. although this next iteration will focus on leveraging the industry's growing digital maturity to offer increased patient value while achieving measurable business goals.

"Australia is poised to establish itself as a global life sciences hub"

Synthetic biology markets are experiencing a surge in demand for molecular diagnostics and technological advances in molecular biology, spurring growth in the Assay and Reagent market in Asia Pacific.

"We're dedicated to Multiple Sclerosis with two approved therapies and Evobrutinib currently in phase 3 trial"

Rare diseases remain untreatable globally despite major advances in research that have enabled us to understand their molecular basis, as well as legislation that provides regulatory and economic incentives to encourage their development.

"Global investors can leverage our deep immunomics platform to develop TCR Cell therapies for solid tumours"

The global biotech ecosystem continues to fluctuate and pose fresh challenges but many emerging enterprises and technologies are keen to collaborate with other stakeholders to solve healthcare challenges.

"We need to foster risky projects that can have large rewards"

Synthetic lethality is a promising area of cancer therapy. Anticancer Bioscience (ACB) is a precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies.

"Technology will play a significant role in reducing numbers of new cases and deaths"

‘Close the care gaps’ – a bold theme set for 2022-2024 World Cancer Day campaigns that fall on February 4 each year – intends to make a huge difference in delivering cancer care to the people.

CANCER THERAPEUTICS GAINING GROUND IN APAC

Cancer, the leading cause of death in most parts of the world, is a veritable Achilles heel for the pharma industry.

Addressing Unmet Patient Needs in Antimicrobial Resistance (AMR): The Vital Role of Industry Partnerships

Interview- Mr Maurizio Luongo and Mr Zhao Hong

Veradigm announces strategic investment in Holmusk from Singapore

US-based Veradigm has announced an investment in Holmusk, a global behavioural health real-world evidence and data analytics company in Singapore, as part of Holmusk’s $45 million series B financing round.

DeepTek introduces new Al powered lumbar spine quantification automation tool

India-based health tech startup DeepTek has announced the global launch of DeepSpine - an artificial intelligence (AI) powered lumbar spine quantification and metrics tool designed to analyse MRI lumbar spine images.

Moderna buys Japanese startup OriCiro for $85M

OriCiro Genomics, founded in December 2018, is focussed on the development and commercialisation of cellfree synthesis

China's ReLive Biotechnologies strengthens presence in regenerative therapy market

Simultaneously with the acquisition, ReLive also completed its Series A financing of $36 million to fund the company’s global ambition.

Seno Medical enters exclusive distributor agreement with Genetik

Seno Medical, based in the US, has entered into an exclusive distributor agreement with Genetik, to market, sell and service the company’s groundbreaking Imagio Opto-Acoustic/ Ultrasound (OA/US) Breast Imaging System.

Malaysian Genomics explores R&D collaboration with SIRIM

Under the strategic cooperation, both parties will evaluate the potential commercial value of a range of genomicsdriven biotechnology R&D projects.

Terumo and Siemens Healthineers collaborate to strengthen cardiac care in India

The collaboration will flag off its efforts with a customised training programme for Cathlab professionals, being developed in partnership with an eminent academic institute in India.

Aculys Pharma, Four H initiate collaboration using wearable devices to study sleep disorders in Japan

In its quest to establish a new pharmaceutical model, Aculys is promoting DX (digital transformation) in clinical trials and medicine.

Lotte Biologics announces $3 B investment plan to leap forward as global CDMO

Lotte Biologics CEO Richard Wonjik Lee has announced a blueprint to leap forward as a global contract development and manufacturing organisation (CDMO).

Sun Pharma buys US-based Concert Pharma for $576 M

Sun Pharma’s immediate focus would be to follow Concert’s plan to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in the first half of 2023.

SK bioscience's shingles vaccine receives biologics license application approval in Malaysia

SKYZoster is shown clinically acceptable immunogenicity and safety at Phase III clinical trial.

Mobile app to help adolescents access public health services in Bangladesh

Millions of adolescents and youth in Bangladesh will be able to access health information and services through two online portals launched recently at The National Adolescent Health Conference held in Dhaka.

New Zealand approves new therapy to treat rare gastrointestinal stromal tumour

Specialised Therapeutics Asia (ST), based in Singapore, has announced that a new therapy to treat rare gastrointestinal stromal tumour (GIST) shown to improve survival has now been approved in New Zealand.

Indonesia's TB response gets $300 M programme World Bank loan

The World Bank’s Board of Executive Directors has approved a $300 million loan to the Indonesian government to improve coverage, quality and efficiency of tuberculosis (TB) response in Indonesia.

Too Much Of A Good Thing...

Thinking long term to ensure that huge amounts of vaccines are not wasted, manufacturers need to have a far-sightedness and not just go on a production spree.

Life Sciences Trends To Watch For In 2023

The past two years have been a rollercoaster ride for the global economy and the pharma industry hasn't been impervious to the major financial upheavals either.

HTAs, CGT Set to Rule Life Sciences Industry in 2023

overnments and other payers make decisions ee the context of the broader economic environment. For 2023 we will continue to see the impact of these global economic trends on payer decisions as they increase financial pressure in the APAC region.

XtalPi joins hands with Singapore’s EDDC

For cancer drug discovery